ReviewBMC medical genomics2026
New insights into HPDL protein: identification of a novel Bi-allelic variant, docking simulation study, and literature review.
Review in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHereditary Spastic Paraplegia (HSP) is a rare neurodegenerative disorder causing progressive weakness and spasticity in the lower limbs. variants in the HPDL gene are linked to Spastic Paraplegia 83 (SPG83), an autosomal recessive form of HSP. While HPDL variants are known to cause SPG83, the molecular mechanisms behind its role remains unclear, mostly due to rare nature of the condition.
methodsThe primary objective was to identify the genetic cause of HSP in two Iranian consanguineous families. Whole-exome sequencing (WES) was employed to identify genetic variants in the probands. Molegro Virtual Docker (MVD), a cutting-edge integrated platform, was utilized to perform protein-ligand docking simulations. This approach aimed to characterize the structural and functional consequences of the identified variants associated with SPG83 pathogenicity.
resultsWES identified two biallelic variants in HPDL: c.3G > C, a start-loss variant abolishing the canonical initiation codon, and c.128G > C, a missense variant. The c.128G > C variant is novel and is documented here for the first time in an SPG83 patient. Trio-based co-segregation analysis confirmed inheritance of variants. Furthermore, a comprehensive literature review revealed a significant consanguinity rate (49.55%) within families harboring HPDL variants.
conclusionThis study expands the genetic and clinical spectrum of HPDL variants. The identification of the genetic variants in the probands underscores the clinical value of genetic testing methods like WES as a valuable diagnostic tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.